Search Results - "Yuste, Susana Romero"

Wells’ Syndrome Successfully Treated with Colchicine by Iglesias Puzas, Álvaro, Mesa Álvarez, Laura, Flórez Menéndez, Ángeles, Romero Yuste, Susana, Prieto Gómez, Olga

“…Eosinophilic cellulitis is an uncommon, inflammatory and chronic disorder of unknown etiology. Corticosteroids are currently considered as the first-line…”
Get full text

Effectiveness of janus kinase inhibitors in relapsing giant cell arteritis in real-world clinical practice and review of the literature by Loricera, Javier, Tofade, Toluwalase, Prieto-Peña, Diana, Romero-Yuste, Susana, de Miguel, Eugenio, Riveros-Frutos, Anne, Ferraz-Amaro, Iván, Labrador, Eztizen, Maiz, Olga, Becerra, Elena, Narváez, Javier, Galíndez-Agirregoikoa, Eva, González-Fernández, Ismael, Urruticoechea-Arana, Ana, Ramos-Calvo, Ángel, López-Gutiérrez, Fernando, Castañeda, Santos, Unizony, Sebastian, Blanco, Ricardo

“…A substantial proportion of patients with giant cell arteritis (GCA) relapse despite standard therapy with glucocorticoids, methotrexate and tocilizumab. The…”
Get full text

Treat-to-target in rheumatoid arthritis: a real-world study of the application and impact of treat-to-target within the wider context of patient management, patient centricity and advanced therapy use in Europe by Taylor, Peter C., Fautrel, Bruno, Piette, Yves, Romero-Yuste, Susana, Broen, Jasper, Welcker, Martin, Howell, Oliver, Rottier, Elke, Zignani, Monia, Van Beneden, Katrien, Caporali, Roberto, Alten, Rieke

“…BackgroundWhile treat-to-target (T2T) is endorsed for the management of rheumatoid arthritis (RA), data on the degree of implementation in clinical practice…”
Get full text

Use of prognostic factors of rheumatoid arthritis in clinical practice and perception of their predictive capacity before and after exposure to evidence by Muñoz-Fernández, Santiago, Otón-Sánchez, Teresa, Carmona, Loreto, Calvo-Alén, Jaime, Escudero, Alejandro, Narváez, Javier, Rodríguez Heredia, Jose Manuel, Romero Yuste, Susana, Vela, Paloma, Luján Valdés, Sara, Royo García, Ana, Baquero, José Luis

“…The aim of the study is to benchmark the use and attributed importance of well-established prognostic factors in rheumatoid arthritis (RA) in daily clinical…”
Get full text

Biologic Disease-modifying antirheumatic drug attributes in the first lines of treatment of rheumatoid arthritis. 2015 ACORDAR project by Muñoz-Fernández, Santiago, Bustabad Reyes, María Sagrario, Calvo Alén, Jaime, Castaño Sánchez, Manuel, Chamizo Carmona, Eugenio, Corominas, Héctor, Fernández-Llanio Comella, Nagore, Hidalgo Calleja, María Cristina, Pérez Venegas, José Javier, Rodríguez Heredia, José Manuel, Romero Yuste, Susana María, Ruiz-Esquide Torino, Virginia

“…To date, between 17% and 35% of patients with rheumatoid arthritis (RA) do not respond as expected to the initial biological therapy. The objective of this…”
Get full text

P118 Baseline Characteristics of and Early Outcomes in the First 200 Patients With Rheumatoid arthritis Treated With Filgotinib in a Prospective Observational Study by Galloway, James, Bevers, Karen, Verschueren, Patrick, Caporali, Roberto, Yuste, Susana Romero, Avouac, Jérôme, Gvozdenovic, Emilia, Harris, Kristina, Zignani, Monia, Burmester, Gerd

“…Abstract Background/Aims Filgotinib (FIL) is a preferential Janus kinase 1 inhibitor, approved in Europe for the treatment of Rheumatoid arthritis (RA). A…”
Get full text

Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions by Cruz-Jentoft, Alfonso J., Romero-Yuste, Susana, Chamizo Carmona, Eugenio, Nolla, Joan M.

“…Introduction Sarcopenia is defined by a loss of muscle mass and function associated with mortality, decreased physical performance, falls, and disability…”
Get full text

Definición de fractura osteoporótica by Caamaño Freire, Manuel, Graña Gil, Jenaro, Hernández Rodríguez, Íñigo, Mosquera Martínez, José Antonio, Romero Yuste, Susana

“…Al igual que sucede en otras áreas geográficas, en Galicia hay un desplazamiento de la intervención terapéutica hacia grupos poblacionales relativamente…”
Get full text

Tratamiento farmacológico de la Osteoporosis by Caamaño Freire, Manuel, Graña Gil, Jenaro, Hernández Rodríguez, Íñigo, Mosquera Martínez, José Antonio, Romero Yuste, Susana

“…El objetivo del tratamiento de la osteoporosis es reducir el riesgo de fractura. Es conveniente no considerar como obje- tivo el aumento de la DMO y recordar…”
Get full text

Situaciones especiales by Caamaño Freire, Manuel, Graña Gil, Jenaro, Hernández Rodríguez, Íñigo, Mosquera Martínez, José Antonio, Romero Yuste, Susana

“…El diagnóstico se realiza según los criterios indicados en el apartado dedicado a la medición de la masa ósea. La prevalencia de OP en el varón es tres veces…”
Get full text

Estudio del paciente con sospecha de Osteoporosis by Caamaño Freire, Manuel, Graña Gil, Jenaro, Hernández Rodríguez, Íñigo, Mosquera Martínez, José Antonio, Romero Yuste, Susana

“…Ante la sospecha de OP recomendamos recoger la siguiente información: edad, raza, antecedentes referidos a hábitos tóxicos (tabaco, alcohol), ingesta dietética…”
Get full text

Nuevas complicaciones by Caamaño Freire, Manuel, Graña Gil, Jenaro, Hernández Rodríguez, Íñigo, Mosquera Martínez, José Antonio, Romero Yuste, Susana

“…La aparición de morbilidad por fracturas por fragilidad en paciente con VIH presenta un incremento en los últimos años probablemente en relación con el aumento…”
Get full text

Effectiveness Of Tocilizumab In Aortitis And Aneurysms Associated With Giant Cell Arteritis by Martín-Gutiérrez, Adrián, Loricera, Javier, Narváez, Javier, Aldasoro, Vicente, Maiz, Olga, Vela, Paloma, Romero-Yuste, Susana, de Miguel, Eugenio, Galíndez-Agirregoikoa, Eva, Fernández-López, Jesús C., Ferraz-Amaro, Iván, Sánchez-Martín, Julio, Moya, Patricia, Campos, Cristina, López-Gutiérrez, Fernando, Castañeda, Santos, Blanco, Ricardo

“…•Tocilizumab (TCZ) shows a rapid clinical and analytical improvement in GCA-patients.•There is an uncoupling between clinical and EULAR remission and imaging…”
Get full text

Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients by Calderón-Goercke, Mónica, Loricera, Javier, Moriano, Clara, Castañeda, Santos, Narváez, Javier, Aldasoro, Vicente, Maiz, Olga, Melero, Rafael, Villa, Juan Ignacio, Vela, Paloma, Romero-Yuste, Susana, Callejas, José Luis, de Miguel, Eugenio, Galíndez-Agirregoikoa, Eva, Sivera, Francisca, Fernández-López, Jesús Carlos, Galisteo, Carles, Ferraz-Amaro, Iván, Sanchéz-Martín, Julio, Sánchez-Bilbao, Lara, González-Gay, Miguel Angel, Hernández, José Luis, Blanco, Ricardo

“…Tocilizumab (TCZ) is the only biologic therapy approved for giant cell arteritis (GCA). There is general agreement on the initial/maintenance dose, duration of…”
Get more information

Integrating different perspectives to define a concept of comprehensive remission in rheumatoid arthritis: The SUMAR project by Balsa, Alejandro, Andreu, José Luis, Hermosa-Hernán, Juan Carlos, León-Navarro, Josefa, Nicolas Pico, Jordi, Venegas, José Javier Pérez, Romero-Yuste, Susana, Sanmarti, Raimon, Torralba Gómez-Portillo, Antonio Ignacio, Valenzuela-Gámez, Juan Carlos, Cohen, Jordi

Get full text

Scurvy. A forgotten pseudovasculitis by Cabaleiro-Raña, Noelia, Santos-Álvarez, Diego, Romar de las Heras, Lucía, Álvarez-Reguera, Carmen, Cervantes Pérez, Evelin Cecilia, Hernández Cancela, Rosa María, Romero-Yuste, Susana

“…Scurvy is a nutritional disease caused by ascorbic acid (vitamin C) deficiency. Althought currently it is a rare disease, we should considerer it in the…”
Get full text

Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients by Calderón-Goercke, Mónica, Castañeda, Santos, Aldasoro, Vicente, Villa, Ignacio, Moriano, Clara, Romero-Yuste, Susana, Narváez, Javier, Gómez-Arango, Catalina, Pérez-Pampín, Eva, Melero, Rafael, Becerra-Fernández, Elena, Revenga, Marcelino, Álvarez-Rivas, Noelia, Galisteo, Carles, Sivera, Francisca, De Miguel, Eugenio, Prieto-Peña, Diana, González-Gay, Miguel Á., Hernández, José L., Blanco, Ricardo

“…To compare the efficacy and safety of TCZ in monotherapy (TCZMONO) vs. combined with conventional immunosuppressive drugs (TCZCOMBO) in Giant Cell Arteritis…”
Get full text

Influence of prognosis factors on the prescription of targeted treatments in rheumatoid arthritis: A Delphi survey by Narváez, Javier, Otón, Teresa, Calvo-Alén, Jaime, Escudero-Contreras, Alejandro, Muñoz-Fernández, Santiago, Rodríguez-Heredia, José Manuel, Romero-Yuste, Susana, Vela-Casasempere, Paloma, Luján, Sara, Baquero, Jose Luis, Carmona, Loreto

“…•It is unclear whether rheumatologist takes into account specific poor prognostic factors when deciding a treatment beyond classic DMARDs in RA.•The effect of…”
Get full text

Biologic therapy in refractory neurobehçet’s disease: a multicentre study of 41 patients and literature review by Herrero-Morant, Alba, Martín-Varillas, José Luis, Castañeda, Santos, Maíz, Olga, Sánchez, Julio, Ortego, Norberto, Raya, Enrique, Prior-Español, Águeda, Moriano, Clara, Melero-González, Rafael B, Graña-Gil, Jenaro, Urruticoechea-Arana, Ana, Ramos-Calvo, Ángel, Loredo-Martínez, Marta, Salgado-Pérez, Eva, Sivera, Francisca, Torre, Ignacio, Narváez, Javier, Andreu, José Luis, Martínez-González, Olga, Torre, Ricardo Gómez-de la, Fernández-Aguado, Sabela, Romero-Yuste, Susana, González-Mazón, Íñigo, Álvarez-Reguera, Carmen, Hernández, José Luis, González-Gay, Miguel Ángel, Blanco, Ricardo, Blanco, Ana, Callejas, José Luis, Brandy-García, Anahy, Olivé, Alejandro, Díez, Elvira, Seijas-López, Álvaro, Delgado-Beltrán, Concepción

“…Abstract Objectives To assess efficacy and safety of biologic therapy (BT) in neurobehçet’s disease (NBD) refractory to glucocorticoids and at least one…”
Get full text

The presence of both HLA-DRB104:01 and HLA-B15:01 increases the susceptibility to cranial and extracranial giant cell arteritis by Prieto-Peña, Diana, Remuzgo-Martínez, Sara, Ocejo-Vinyals, Javier Gonzalo, Atienza-Mateo, Belen, Genre, Fernanda, Muñoz-Jimenez, Alejandro, Ortiz-Sanjuán, Francisco, Romero-Yuste, Susana, Moriano, Clara, Galindez-Agirregoikoa, Eva, Calvo, Itziar, Ortego-Centeno, Norberto, Álvarez-Rivas, Noelia, Miranda-Filloy, José A, Llorente, Irene, García-García, Javier, Blanco, Ricardo, Gualillo, Oreste, Martin, Javier, Castañeda, Santos, Lopez-Mejías, Raquel, González-Gay, Miguel A

“…To determine if patients with the predominant extracranial large-vessel-vasculitis (LVV) pattern of giant cell arteritis (GCA) have a distinctive HLA-B…”
Get more information